Aytu BioPharma Files 8-K on Security Holder Vote
Ticker: AYTU · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
AYTU shareholders might be voting on something soon, details TBD.
AI Summary
On June 26, 2024, AYTU BIOPHARMA, INC. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. No specific details regarding the nature of the vote or the matters to be voted upon were provided in the excerpt.
Why It Matters
This filing signals a potential upcoming decision or event that requires shareholder approval, which could impact the company's future direction or operations.
Risk Assessment
Risk Level: medium — The filing indicates a vote by security holders, which could lead to significant corporate actions or changes that carry inherent risks.
Key Players & Entities
- AYTU BIOPHARMA, INC. (company) — Registrant
- June 26, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 7900 E. Union Avenue, Suite 920 Denver, CO 80237 (address) — Principal Executive Offices
FAQ
What specific matters will be submitted to a vote of AYTU BIOPHARMA, INC.'s security holders?
The provided excerpt does not specify the exact matters to be voted upon by security holders.
When is the vote by security holders expected to take place?
The filing date is June 26, 2024, and it reports on the submission of matters to a vote, but does not specify a future date for the vote itself.
Has AYTU BIOPHARMA, INC. previously changed its name?
Yes, the company was formerly known as AYTU BIOSCIENCE, INC. and Rosewind CORP.
What is the principal business of AYTU BIOPHARMA, INC. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are AYTU BIOPHARMA, INC.'s principal executive offices located?
The principal executive offices are located at 7900 E. Union Avenue, Suite 920, Denver, CO 80237.
Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-26 16:36:36
Key Financial Figures
- $0.0001 — ch Registered Common Stock , par value $0.0001 per share AYTU The NASDAQ Stock Mar
Filing Documents
- aytu20240607_8k.htm (8-K) — 36KB
- logo01.jpg (GRAPHIC) — 4KB
- 0001437749-24-021296.txt ( ) — 179KB
- aytu-20240626.xsd (EX-101.SCH) — 3KB
- aytu-20240626_def.xml (EX-101.DEF) — 12KB
- aytu-20240626_lab.xml (EX-101.LAB) — 15KB
- aytu-20240626_pre.xml (EX-101.PRE) — 12KB
- aytu20240607_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 26, 2024, Aytu BioPharma, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "2024 Annual Meeting"). At the close of business on April 29, 2024, the record date for the 2024 Annual Meeting, there were 5,568,075 shares of the Company's common stock issued and outstanding with each share being entitled to one vote and to be voted together as one class at the 2024 Annual Meeting. At the 2024 Annual Meeting, there were present in person or by proxy 4,037,162 shares of the Company's common stock, representing stockholders entitled to vote of approximately 73% of the total issued and outstanding on the record date and constituting a quorum. Set forth below are the voting results for the three proposals considered and voted upon at the 2024 Annual Meeting, all of which were described in the Proxy Statement filed with the United States Securities and Exchange Commission on May 10, 2024: Proposal No. 1 - Election of Directors The Company's stockholders elected all of the incumbent directors that stood for reelection. Each director was elected by a majority vote. The directors elected and the final vote tabulation for each director is as follows: Director Votes Cast For Votes Withheld Broker Non-Votes Joshua R. Disbrow 2,111,846 596,291 1,329,025 John A. Donofrio, Jr. 2,068,029 640,108 1,329,025 Carl C. Dockery 2,055,295 652,842 1,329,025 Abhinav "Abi" Jain 2,074,470 633,667 1,329,025 Vivian H. Liu 2,067,904 640,233 1,329,025 Proposal No. 2 - Appointment of Independent Registered Public Accounting Firm The Company's stockholders approved the proposal to ratify the appointment by the Company's Audit committee of Grant Thornton LLP, as the Company's independent registered public accounting firm for the fiscal year ended June 30, 2024. The final vote tabulation for this proposal is as follows: Votes Cast For Votes Cast Against Votes Cast Abstain
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AYTU BIOPHARMA, INC. Date: June 26, 2024 By: /s/ Mark K. Oki Mark K. Oki Chief Financial Officer